Evidence map›Paper›PMID 42449588›Full record

ReviewCancers2026

From Excision to Immunity: The Full Spectrum of Modern Melanoma Treatments.

Vimal Murugesan, Thusanth Thuraisingam, Danuta Radzioch

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Vimal MurugesanDepartment of Experimental Medicine, McGill University, Montreal, QC H4A 3J1, Canada.ORCID 0000-0003-3205-3038
Thusanth ThuraisingamDivision of Dermatology, Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.ORCID 0009-0001-2627-7855
Danuta RadziochDepartment of Experimental Medicine, McGill University, Montreal, QC H4A 3J1, Canada.ORCID 0000-0002-1601-2757

Funding

CIHR CIHR263978-RIMUHC11463D2R Training Award T-FDN2-A2-105
6 · The paper itself

Abstract

Cutaneous Melanoma is a biologically heterogeneous malignancy. Although recent therapeutic advances have improved survival, durable remissions remain elusive for many patients. Surgical excision with stage-appropriate margins and selective nodal staging remains the cornerstone of curative-intent management. In contrast, conventional cytotoxic chemotherapy now plays a limited, largely palliative role given its modest efficacy and substantial toxicity. Targeted therapy with BRAF/MEK inhibitors has improved outcomes in patients with

Indexed as

chemotherapycutaneous melanomaimmunotherapysurgerytargeted therapy

Identifiers

PMID42449588
PMCPMC13359695

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.